Skip to content

Influence of Light on Sleep, Awakening, Electroencephalogram (EEG) and Cognitive Performances

Influence of Light on Sleep, Awakening, Electroencephalogram (EEG) and Cognitive Performances, and Medical Technology Assessment for Registration and Long-term EEG Analysis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02858765
Acronym
CHRONOSOMNO
Enrollment
92
Registered
2016-08-08
Start date
2016-06-30
Completion date
2019-06-30
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Sleep and Chronobiology

Brief summary

The purpose of this project is to study the influence of light on sleep, wakefulness, EEG activity and cognitive performances. The study aim also to evaluate techniques for registration and analysis of the EEG over periods of time.

Interventions

OTHERApplication of white polychromatic light for 2h30 at different times of day

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female * Aged 18 to 40 years * With a hint of Bodymass index (BMI) between 17 and 30 kg.m - 2 * Healthy subject determined by a clinical examination, a psychological interview, a blood test, a urine analysis and an ophthalmologic examination * Topic Subject with a score \<6 questionnaire PSQI (Sleep Questionnaire Pittsburgh) * Subject agreeing to maintain a regular sleep/wake rhythm during the study * Subject agreeing to refrain from caffeine, nicotine, alcohol, psychotropic drugs, cannabis or other drugs during the study * Signed informed consent * Subject affiliated to a social protection scheme

Exclusion criteria

* somatic diseases: cardiovascular, respiratory, gastrointestinal, hematopoietic, Visual * immune system diseases * kidneys and urinary tract diseases * endocrine and metabolic diseases * neurological diseases * infectious diseases * thrombocytopenia or other malfunction of blood platelets * Subject with risk of thrombosis, including subject with a history of phlebitis, smoker under oral contraceptive... * Subject with an addiction to caffeine, nicotine, alcohol, psychotropic drugs, cannabis, or any other drug * Subject treatment contraindicated or inadvisable in combination with heparin * Allergy to neoprene or lycra * Dysfunction of the temporomandibular joint (TMJD) * Blood donation in the previous 3 months before the inclusion * Participation in other clinical trials in the previous 3 months before the inclusion * Work by shifts in the year preceding the inclusion * Trans-meridian travel (\> 2 time zones) in the month previous the inclusion * Contraindications to the use of the medical device * Impossibility to give enlightened information (subject in an emergency situation, understanding difficulties,...) * Subject under safeguard of justice * Subject under tutorship or curatorship * Pregnancy (women of childbearing age) * Breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Analysis of EEG activityup to 56 hourssleep fragmentation
Cognitive performances assessed using Psychomotor vigilance task (PVT)up to 56 hoursPsychomotor vigilance task (PVT)
Cognitive performances assessed using Sustained Attention to Response Task (SART)up to 56 hoursSustained Attention to Response Task (SART)
Cognitive performances assessed using Digit Symbol Substitution Test (DSST)up to 56 hoursDigit Symbol Substitution Test (DSST)
Cognitive performances assessed using N-back tasksup to 56 hoursN-back tasks
Cognitive performances assessed using Paced Visual Serial Addition Task (PVSAT)up to 56 hoursPaced Visual Serial Addition Task (PVSAT)
Cognitive performances assessed using Visual analogue scales (VAS) for motivationup to 56 hoursVisual analogue scales (VAS) for motivation
Cognitive performances assessed using Positive and Negative Affect Scale (PANAS)up to 56 hoursPositive and Negative Affect Scale (PANAS)
Cognitive performances assessed using Karolinska Sleepiness Scale (KSS)up to 56 hoursKarolinska Sleepiness Scale (KSS)
Cognitive performances assessed using Visual Comfort Scale (VCS)up to 56 hoursVisual Comfort Scale (VCS)
Cognitive performances assessed using Racing and Crowded Thoughts Questionnaire (RCTQ)up to 56 hoursRacing and Crowded Thoughts Questionnaire (RCTQ)
Cognitive performances assessed using Mental Effort Rating Scale (RSME)up to 56 hoursMental Effort Rating Scale (RSME)
Cognitive performances assessed using Karolinska Drowsiness Test (KDT)up to 56 hoursKarolinska Drowsiness Test (KDT)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026